Dry powder nasal drug delivery: challenges, opportunities and a study of the commercial Teijin Puvlizer Rhinocort device and formulation
- 22 March 2016
- journal article
- research article
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 42 (10) , 1660-1668
Abstract
Purpose: To discuss the challenges and opportunities for dry powder nasal medications and to put this in to perspective by evaluating and characterizing the performance of the Teijin beclomethasone dipropionate (BDP) dry powder nasal inhaler; providing a baseline for future nasal products development. Methods: The aerosol properties of the formulation and product performance of Teijin powder intranasal spray were assessed, with a particular focus on particle size distribution (laser diffraction), powder formulation composition (confocal Raman microscope) and aerosol performance data (British Pharmacopeia Apparatus E cascade impactor, aerosol laser diffraction). Results: Teijin Rhinocort® (BDP) dry powder spray formulation is a simple blend of one active ingredient, BDP with hydroxypropylcellulose (HPC) carrier particles and a smaller quantity of lubricants (stearic acid and magnesium stearate). The properties of the blend are mainly those of the carrier (Dv50 = 98 ± 1.3 µm). Almost the totality of the capsule fill weight (96.5%) was emitted with eight actuations of the device. Using the pharmacopeia suggested nasal chamber deposition apparatus attached to an Apparatus E impactor. The BDP main site of deposition was found to be in the nasal expansion chamber (90.2 ± 4.78%), while 4.64 ± 1.38% of the BDP emitted dose was deposited on Stage 1 of the Apparatus E. Conclusions: The Teijin powder nasal device is a simple and robust device to deliver pharmaceutical powder to the nasal cavity, thus highlighting the robustness of intranasal powder delivery systems. The large number of actuations needed to deliver the total dose (eight) should be taken in consideration when compared to aqueous sprays (usually two actuations), since this will impact on patient compliance and consequently therapeutic efficacy of the formulation.Keywords
This publication has 27 references indexed in Scilit:
- Nasal drug delivery devices: characteristics and performance in a clinical perspective—a reviewDrug Delivery and Translational Research, 2012
- Brain distribution of ribavirin after intranasal administrationAntiviral Research, 2011
- Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: A randomised, placebo-controlled studyCephalalgia, 2010
- A computational fluid dynamics approach to assess interhuman variability in hydrogen sulfide nasal dosimetryInhalation Toxicology, 2010
- Preparation andin vivostudy of dry powder microspheres for nasal immunizationJournal of Drug Targeting, 2009
- Rapid absorption of sumatriptan powder and effects on glyceryl trinitrate model of headache following intranasal delivery using a novel bi-directional deviceJournal of Pharmacy and Pharmacology, 2009
- Development and testing of particulate formulations for the nasal delivery of antibodiesJournal of Controlled Release, 2009
- Sniff Nasal Inspiratory Pressure in Healthy Japanese Subjects: Mean Values and Lower Limits of NormalRespiration, 2008
- Effect of Water Content on the Structural Reorganization and Elastic Properties of Biopolymer Films: A Comparative StudyBiomacromolecules, 2007
- Effect of Humidity on Aerosolization of Micronized DrugsDrug Development and Industrial Pharmacy, 2003